2019
Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer
Pumpalova Y, Kozak MM, von Eyben R, Kunz P, Fisher G, Chang DT, Haraldsdottir S. Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. Journal Of Gastrointestinal Oncology 2019, 10: 605-615. PMID: 31392040, PMCID: PMC6657317, DOI: 10.21037/jgo.2019.02.17.Peer-Reviewed Original ResearchAnal cancer patientsIncidence of recurrenceAnal cancerDefinitive chemoradiationOverall survivalCancer patientsLonger recurrence-free intervalCancer-specific survivalDisease-specific survivalRecurrence-free intervalSignificant lower incidenceLoco-regional relapseLog-rank testMann-Whitney U testAnal painMore colostomiesLocoregional recurrencePatient characteristicsRectal cancerOverall incidenceGray's testLower incidenceCommon gradePatientsRecurrence
2018
A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution.
Pumpalova Y, Kozak M, von Eyben R, Kunz P, Fisher G, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution. Journal Of Clinical Oncology 2018, 36: e15573-e15573. DOI: 10.1200/jco.2018.36.15_suppl.e15573.Peer-Reviewed Original ResearchA 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford.
Pumpalova Y, Kozak M, von Eyben R, Fisher G, Kunz P, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford. Journal Of Clinical Oncology 2018, 36: 710-710. DOI: 10.1200/jco.2018.36.4_suppl.710.Peer-Reviewed Original ResearchAnal cancer patientsDisease-specific survivalCancer patientsFM groupCM groupDefinitive chemoradiationColostomy rateExact testCommon grade 2Higher colostomy rateIncidence of recurrenceLoco-regional recurrenceLog-rank testCause of deathFisher's exact testMann-Whitney U testAnal painInduction chemotherapyAnal cancerDefinitive radiotherapyDistant recurrenceOverall survivalMedian ageMost recurrencesRectal cancer
2016
Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review
Leeds IL, Alturki H, Canner JK, Schneider EB, Efron JE, Wick EC, Gearhart SL, Safar B, Fang SH. Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review. World Journal Of Surgical Oncology 2016, 14: 208. PMID: 27495294, PMCID: PMC4974747, DOI: 10.1186/s12957-016-0970-x.Peer-Reviewed Original ResearchMeSH KeywordsAbdomenAdultAge FactorsAgedAnus NeoplasmsCarcinoma, Squamous CellComorbidityFemaleFollow-Up StudiesHealth Status DisparitiesHIV InfectionsHospital MortalityHumansIncidenceLength of StayMaleMiddle AgedNeoplasm Recurrence, LocalPerineumPostoperative ComplicationsRetrospective StudiesRisk FactorsSalvage TherapyTreatment OutcomeConceptsHIV-positive patientsLength of stayHIV-negative patientsAnal cancerNational Inpatient SampleAbdominoperineal resectionHospitalization costsHIV infectionAnal squamous cell cancerAnal squamous cell carcinomaUtilization Project National Inpatient SampleGreater hospitalization costsWorse postoperative recoveryHIV-positive groupMethodsA retrospective reviewAnal cancer patientsSquamous cell cancerHuman immunodeficiency virusMultivariable logistic regressionSquamous cell carcinomaHospital mortalityHospital stayPerioperative complicationsPostoperative hemorrhagePostoperative outcomesNomogram for Predicting Overall Survival and Salvage Abdominoperineal Resection for Patients with Anal Cancer
Tsikitis VL, Lu KC, Kim JS, Billingsley KG, Thomas CR, Herzig DO. Nomogram for Predicting Overall Survival and Salvage Abdominoperineal Resection for Patients with Anal Cancer. Diseases Of The Colon & Rectum 2016, 59: 1-7. PMID: 26651105, DOI: 10.1097/dcr.0000000000000507.Peer-Reviewed Original ResearchSalvage abdominoperineal resectionAbdominoperineal resectionOverall survivalAnal cancerSalvage surgeryNodal statusTumor sizeStratified Cox proportional hazards modelCox proportional hazards modelAnal cancer treatmentNational Cancer DatabaseRetrospective cohort studyAnal cancer patientsYear of diagnosisTNM clinical stagePredicting Overall SurvivalOverall survival modelProportional hazards modelLogistic regression modelsSphincter preservationChemoradiation therapyCohort studySurgery statusChemoradiotherapy treatmentClinical stage
2015
Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center
Bitterman DS, Grew D, Gu P, Cohen RF, Sanfilippo NJ, Leichman CG, Leichman LP, Moore HG, Gold HT, Du KL. Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center. Journal Of Gastrointestinal Oncology 2015, 6: 524-33. PMID: 26487947, PMCID: PMC4570920, DOI: 10.3978/j.issn.2078-6891.2015.061.Peer-Reviewed Original ResearchDisease-free survivalColostomy-free survivalOverall survivalPublic hospital patientsPrivate hospital patientsHospital patientsRadiotherapy durationFree survivalRadiotherapy delayRadiation therapyHigher clinical T stageThree-year overall survivalPoor disease-free survivalPrivate hospitalsAdvanced anal cancerAnal cancer outcomesSame cancer centerUnplanned treatment breaksClinical T stageAnal cancer patientsKaplan-Meier methodLow socioeconomic status populationClinical stage groupsLog-rank testProportional hazards model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply